BACE1 and Alzheimer disease: Ongoing clinical trials with active or passive immunotherapy agents [26], with agents that reduce the Aβ plaque burden [27,28], with α-secretase modulators [29] or BACE inhibitors [25] are enrolling prodromal or mild AD patients to test the hypothesis of early pharmacological intervention [3,8].